We are live on ! Find out more
KAM

Kazazian Asset Management Portfolio holdings

AUM $91.5M
1-Year Est. Return 35.36%
This Fund
S&P 500
This Quarter Est. Return
+7.54%
1 Year Est. Return
+35.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$81.7M
AUM Growth
+$15.6M
Cap. Flow
+$11.7M
Cap. Flow %
14.33%
Top 10 Hldgs %
57.21%
Holding
75
New
23
Increased
16
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$1.33M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$933K
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$879K
4
CMG icon
Chipotle Mexican Grill
CMG
+$876K
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$719K

Top Sells

Rank Stock Value
1
EWZ icon
iShares MSCI Brazil ETF
EWZ
+$888K
2
PRGO icon
Perrigo
PRGO
+$529K
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$387K
4
GREK
Global X MSCI Greece ETF
GREK
+$365K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$354K

Sector Composition

Rank Sector Weight
1 Healthcare 24.22%
2 Consumer Discretionary 11.94%
3 Financials 11.46%
4 Communication Services 8%
5 Real Estate 4.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$318B
$747K 0.91%
12,222
+5,045
+70% +$306K
PMT
27
PennyMac Mortgage Investment
PMT
$842M
$731K 0.89%
42,045
– –
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
$708K 0.87%
14,577
+6,019
+70% +$328K
TSRO
29
DELISTED
TESARO, Inc.
TSRO
$677K 0.83%
+5,246
New +$651K
PTLA
30
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$661K 0.81%
+12,241
New +$719K
ABT icon
31
Abbott
ABT
$187B
$570K 0.7%
10,688
– –
BLUE
32
DELISTED
bluebird bio
BLUE
$561K 0.69%
315
+130
+70% +$182K
GBT
33
DELISTED
Global Blood Therapeutics, Inc.
GBT
$543K 0.66%
+17,492
New +$492K
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
$511K 0.63%
+14,582
New +$198K
NETI
35
DELISTED
Eneti Inc.
NETI
$510K 0.62%
7,781
– –
ICPT
36
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$503K 0.62%
+8,666
New +$933K
PBYI icon
37
Puma Biotechnology
PBYI
$454M
$489K 0.6%
4,083
+1,690
+71% +$157K
DO
38
DELISTED
Diamond Offshore Drilling
DO
$479K 0.59%
+33,000
New +$397K
GSK icon
39
GSK
GSK
$106B
$473K 0.58%
9,330
+3,850
+70% +$195K
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.55B
$466K 0.57%
8,747
+5,323
+155% +$315K
AAMC
41
DELISTED
Altisource Asset Management Corp
AAMC
$435K 0.53%
9,860
– –
CXO
42
DELISTED
CONCHO RESOURCES INC.
CXO
$435K 0.53%
+3,300
New +$397K
CTRA
43
DELISTED
Coterra Energy
CTRA
$425K 0.52%
+15,900
New +$404K
PTEN icon
44
Patterson-UTI
PTEN
$3.76B
$419K 0.51%
+20,000
New +$368K
NBL
45
DELISTED
Noble Energy, Inc.
NBL
$408K 0.5%
+14,400
New +$379K
AZN icon
46
AstraZeneca
AZN
$250B
$395K 0.48%
5,832
+696
+14% +$44K
APA icon
47
APA Corp
APA
$13.2B
$389K 0.48%
+8,500
New +$375K
LJPC
48
DELISTED
La Jolla Pharmaceutical Company
LJPC
$382K 0.47%
+10,992
New +$353K
GM.WS.B
49
DELISTED
General Motors Company
GM.WS.B
$377K 0.46%
16,814
– –
IMGN
50
DELISTED
Immunogen Inc
IMGN
$357K 0.44%
+46,644
New +$310K
1
2
3

Similar funds

MRP
Measured Risk Portfolios San Diego, California $91.4M AUM 0.88% 1-Year Est. Return
ITG
Index Technologies Group New York $91.8M AUM
MA
Marquette Associates Chicago, Illinois $91.9M AUM 13.47% 1-Year Est. Return
AW
Aspirean Wealth Mill Valley, California $92.1M AUM
SPCM
Spruce Point Capital Management New York $90.9M AUM
ML
MLP3 LLC Linwood, New Jersey $90.7M AUM
ICM
Incision Capital Management San Francisco, California $90.6M AUM
ACMC
Anchor Capital Management Company Raleigh, North Carolina $92.7M AUM 19.36% 1-Year Est. Return

Kazazian Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Kazazian Asset Management held 75 positions worth $81.7M, up 24% from $66.1M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Kazazian Asset Management deployed $11.7M of net new capital in Q3 2017, opening 23 new positions and adding to 16 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 8,666 shares worth $503K.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $387K trimmed.

  • Kazazian Asset Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 8,666 shares worth $503K.
  • Kazazian Asset Management added most to Biogen in Q3 2017, an estimated $1.33M increase.
  • Kazazian Asset Management's biggest Q3 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $387K.
  • Kazazian Asset Management fully exited iShares MSCI Brazil ETF in Q3 2017, selling an estimated $888K.
  • Kazazian Asset Management's ten largest holdings make up 57% of its $81.7M portfolio in Q3 2017.
  • Kazazian Asset Management opened 23 new positions and closed 5 in Q3 2017.
  • Kazazian Asset Management's portfolio value rose 24% quarter-over-quarter to $81.7M.

Based on Kazazian Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.